Therapeutic consequences of molecular biology advances in oncology;Conséquences thérapeutiques des progrès de la biologie moléculaire en oncologie

Bulletin du Cancer

Volumn 96, Issue 1, 2009, Pages 59-71

  Bauvet, F ^a   Awada, A ^b   Gil, T ^b   Hendlisz, A ^b  

^a IRIS   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast; Cancer; Colorectal; Kidney; Molecular biology; Molecular targeted therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INTERFERON; INTERLEUKIN 2; IRINOTECAN; LAPATINIB; METHOTREXATE; OXALIPLATIN; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CHROMOSOME 18Q; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HETEROZYGOTE; HUMAN; KIDNEY CANCER; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; ONCOGENE NEU; ONCOLOGY; PREDICTIVE VALIDITY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; BREAST TUMOR; COLORECTAL TUMOR; FEMALE; GENETICS; IMMUNOTHERAPY; KIDNEY TUMOR; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PROTO ONCOGENE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MOLECULAR BIOLOGY; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 61549132836     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0796     Document Type: Review

References (64)

1. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005 ; 353 : 1652-4.
2. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project : prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990 ; 8 : 103-12.
3. Gligorov J, Selle F, Khalil A, Abbas F, Namer M, Lotz JP. Updates on gemcitabine on metastatic breast cancer. Bull Cancer 2007 ; 94 : S90-4.
4. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001 ; 19 : 2587-95.
5. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer : multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003 ; 21 : 2889-95.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1659-72.
7. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer : a randomised controlled trial. Lancet 2007 ; 369 : 29-36.
8. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002 ; 20 : 1215-21.
9. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016 : a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002 ; 21 : 6255-63.
10. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006 ; 66 : 1630-9.
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747-52.
12. De Soto JA, Deng CX. PARP-1 inhibitors : are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 2006 ; 3 : 117-23.
13. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003 ; 3 : 401-10.
14. Miller K, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 ; 23 : 792-9.
15. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 ; 357 : 2666-76.
16. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005 ; 353 : 793-802.
17. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004 ; 351 : 781-91.
18. Van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Vos-kuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009.
19. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 281 7-26.
20. Montie JE, Bukowski RM, Deodhar SH, Hewlett JS, Stewart BH, Straffon RA. Immunotherapy of disseminated renal cell carcinoma with transfer factor. J Urol 1977 ; 11 7 : 553-6.
21. Mickisch GH. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol 2003 ; 43 : 670-9.
22. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma : a computer analysis. J Urol 1978 ; 120 : 148-52.
23. Medical Research Council Renal Cancer Collaborators. Interferon a and survival in metastatic renal carcinoma : early results of a randomised controlled trial. Lancet 1999 ; 353 : 14-7.
24. Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tam- mela T, et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999 ; 17 : 2859-67.
25. Atkins MB, Sparano J, Fisher Rl, Weiss CR, Margolin KA, Fink Kl, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon α-2b in advanced renal cell carcinoma. J Clin Oncol 1993 ; 11 : 661-70.
26. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998 ; 338 : 1272-8.
27. Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, et al. Cytokines in metastatic renal cell carcinoma : is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 1999 ; 1 7 : 2039-43.
28. Kim WY, Kaelin WG. Cytokines in metastatic renal cell carcinoma : role of VHL gene mutation in human cancer. J Clin Oncol 2004 ; 22 : 4991-5004.
29. Richard S, Ladroue C, Gad S, Giraud S, Gardie B. Genetics and angiogenesis : the example of von Hippel-Lindau disease. Bull Cancer 2007 ; 94 : S170-9.
30. Marston W, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Innovations and challenges in renal cancer. Identification of the genes for kidney cancer : opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007 ; 13 : 671-9.
31. Rini Bl, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005 ; 23 : 1028-43.
32. Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O. Angiogenesis and renal cell carcinoma. Bull Cancer 2007 ; 94 : S232-40.
33. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Négrier S, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008 ; 26(Suppl.) (abstr 5024).
34. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 ; 356 : 125-34.
35. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti- vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349 : 427-34.
36. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma : a randomised, double-blind phase III trial. Lancet 2007 ; 370 : 2103-11.
37. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon a, or both for advanced renal cell carcinoma. N Engl J Med 2007 ; 356 : 2271-81.
38. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 ; 372 : 449-56.
39. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Fer- rara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999 ; 1 7 : 2530.
40. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines. Ann Oncol 2002 ; 13 : 1460-8.
41. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer : implications for targeted cancer therapy. Rev Urol 2007 ; 9 : 47-56.
42. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study. J Clin Oncol 2004 ; 22 : 229-37.
43. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000 ; 342 : 69-77.
44. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998 ; 16 : 427-33.
45. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele Jr. G, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996 ; 335 : 1 727-32.
46. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten-ras mutations in patients with colorectal cancer : the multi- center 'RASCAL' study. J Natl Cancer Inst 1998 ; 90 : 675-84.
47. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer : results from the UK MRC FOCUS trial. J Clin Oncol 2008 ; 26 : 2690-8.
48. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluoro-uracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 ; 349 : 247-57.
49. Tejpar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F, et al. Phase l/ll study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST) : pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007 ; 25 : 4037.
50. Lièvre A, Laurent-Puig P. Predictive factors of response to anti-EGFR treatments in colorectal cancer. Bull Cancer 2008 ; 95 : 133-40.
51. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005 ; 23 : 1803-10.
52. Capuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008 ; 19 : 717-23.
53. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Fol- precht G, et al. K-ras status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOL- FIRI with or without cetuximab : The CRYSTAL experience. J Clin Oncol 2008 ; 26(suppl) (abstr 2).
54. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type K-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008 ; 26 : 1626-34.
55. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. K-ras mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008 ; 26 : 374-9.
56. Laurent-Puig P, Lievre A, Ducreux M, Loriot MA. The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer. Bull Cancer 2008 ; 95 : 935-42.
57. Loupakis F, Pollina L, Stasi I, Masi G, Funel N, Scartozzi M, et al. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. J Clin Oncol 2008 ; 26(suppl) (abstr 4003).
58. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, San- toro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 ; 351 : 337-45.
59. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 2007 ; 25 : 1 658-64.
60. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volo- vat C, Nippgen J, et al. K-ras status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab : The OPUS experience. J Clin Oncol 2008 ; 26(suppl) (abstr 4000).
61. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hains- worth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
62. Giantonio B), Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 ; 25 : 1 539-44.
63. Purdie DM, Berlin JD, Flynn PJ, Grothey A, Kabbinavar FF, Koz- loff MF, et al. The safety of long-term bevacizumab use : results from the BRiTE observational cohort study. J Clin Oncol 2008 ; 26(suppl) (abstr 4103).
64. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, Schrama JG, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIR02 study of the Dutch Colorectal Cancer Group. J Clin Oncol 2008 ; 26(suppl) (abstr 4011).